Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations.

The MDR1 multidrug transporter plays a key role in determining drug bioavailability, and differences in drug response exist amongst different ethnic groups. Numerous studies have identified an association between the MDR1 single nucleotide polymorphism (SNP) exon 26 3435C>T and differences in MDR1 function. We performed a haplotype analysis of the MDR1 gene in three major ethnic groups (Chinese, Malays and Indians) by examining 10 intragenic SNPs. Four were polymorphic in all three ethnic groups: one occurring in the non-coding region and three occurring in coding exons. All three coding SNPs (exon 12 1236C>T, exon 21 2677G>T/A and exon 26 3435C>T) were present in high frequency in each ethnic group, and the derived haplotype profiles exhibited distinct differences between the groups. Fewer haplotypes were observed in the Malays (n = 6) compared to the Chinese (n = 10) and Indians (n = 9). Three major haplotypes (> 10% frequency) were observed in the Malays and Chinese; of these, two were observed in the Indians. Strong linkage disequilibrium (LD) was detected between the three SNPs in all three ethnic groups. The strongest LD was present in the Chinese, followed by Indians and Malays, with the corresponding LD blocks estimated to be approximately 80 kb, 60 kb and 40 kb, respectively. These data strongly support the hypothesis that strong LD between the neutral SNP exon 26 3435C>T and a nearby unobserved causal SNP underlies the observed associations between the neutral SNP and MDR1 functional differences. Furthermore, strong LD between exon 26 3435T and different unobserved causal SNPs in different study populations may provide a plausible explanation for conflicting reports associating the same exon 26 3435T allele with different MDR1 functional changes.

[1]  A. Schinkel,et al.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.

[2]  D. Nebert,et al.  Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? , 1999, Clinical genetics.

[3]  C. Hrycyna,et al.  Molecular genetic analysis and biochemical characterization of mammalian P-glycoproteins involved in multidrug resistance. , 2001, Seminars in cell & developmental biology.

[4]  U. Brinkmann,et al.  Frequency of C3435T polymorphism of MDR1 gene in African people , 2001, The Lancet.

[5]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.

[6]  R D Klausner,et al.  Structure and dynamics of the iron responsive element RNA: implications for binding of the RNA by iron regulatory binding proteins. , 1997, Journal of molecular biology.

[7]  L. Brooks,et al.  A DNA polymorphism discovery resource for research on human genetic variation. , 1998, Genome research.

[8]  Nebert Dw.  Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? , 1997, American journal of human genetics.

[9]  J. R. Roesser,et al.  RNA secondary structure: an important cis-element in rat calcitonin/CGRP pre-messenger RNA splicing. , 1998, Biochemistry.

[10]  I. Pastan,et al.  HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. , 1998, Biochemistry.

[11]  U. Brinkmann,et al.  Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. , 2001, Drug discovery today.

[12]  M. Gottesman,et al.  HIV-1 protease inhibitors and the MDR1 multidrug transporter. , 1998, The Journal of clinical investigation.

[13]  Jacques Fellay,et al.  Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.

[14]  U. Brinkmann,et al.  ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. , 2001, Pharmacogenomics.

[15]  R. Kim,et al.  Identification of functionally variant MDR1 alleles among European Americans and African Americans , 2001, Clinical pharmacology and therapeutics.

[16]  K Ueda,et al.  Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. , 1990, The Journal of biological chemistry.

[17]  S. Higuchi,et al.  Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. , 2001, Pharmacogenetics.

[18]  J. Kigawa,et al.  Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. , 2001, The Journal of pharmacology and experimental therapeutics.

[19]  D. Roden,et al.  The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.

[20]  V. Armstrong,et al.  No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. , 2001, Clinical chemistry.

[21]  Yoshinori Morita,et al.  MDR1 Genotype-Related Pharmacokinetics of Digoxin After Single Oral Administration in Healthy Japanese Subjects , 2001, Pharmaceutical Research.

[22]  H. McLeod,et al.  MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. , 2001, Pharmacogenetics.

[23]  M. Gottesman.  Multidrug resistance during chemical carcinogenesis: a mechanism revealed? , 1988, Journal of the National Cancer Institute.

[24]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.

[25]  R. Kim,et al.  Molecular basis of ethnic differences in drug disposition and response. , 2001, Annual review of pharmacology and toxicology.

[26]  C. Meisel,et al.  Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects , 2001, Clinical pharmacology and therapeutics.

[27]  N. Morton,et al.  Allelic association with SNPs: Metrics, populations, and the linkage disequilibrium map , 2001, Human Mutation.

[28]  U. Brinkmann,et al.  How to Manage Individualized Drug Therapy: Application of Pharmacogenetic Knowledge of Drug Metabolism and Transport , 2000, Clinical chemistry and laboratory medicine.

[29]  I. Roninson,et al.  An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene , 1988, Cell.

[30]  M. Fromm,et al.  The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. , 2001, Pharmacogenetics.

[31]  G. Varani,et al.  Specificity of ribonucleoprotein interaction determined by RNA folding during complex formation , 1996, Nature.

[32]  Lee Cg,et al.  The role of single nucleotide polymorphisms (SNPs) in understanding complex disorders and pharmacogenomics. , 2000 .

[33]  L. Excoffier,et al.  Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. , 1995, Molecular biology and evolution.

[34]  Pardis C Sabeti,et al.  Linkage disequilibrium in the human genome , 2001, Nature.

[35]  J. Basilion,et al.  Single-nucleotide polymorphisms can cause different structural folds of mRNA. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  I. Pastan,et al.  Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. , 1995, Cancer research.

[37]  U. Brinkmann,et al.  Polymorphisms in the ABC drug transporter gene MDR1 , 2001, The Pharmacogenomics Journal.

[38]  I. Tinoco,et al.  The structure of an RNA pseudoknot that causes efficient frameshifting in mouse mammary tumor virus. , 1995, Journal of molecular biology.

[39]  P. Joyce,et al.  A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression , 2002, The Pharmacogenomics Journal.

[40]  HL McLeod.  Pharmacokinetic differences between ethnic groups , 2002, The Lancet.

[41]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.